Cargando…
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
BACKGROUND: Immunotherapy has revolutionised the treatment of advanced cutaneous squamous cell carcinoma (cSCC). It is important to understand both safety and efficacy in a real-world and trial-ineligible cSCC population. We aimed to evaluate safety, efficacy and molecular insights among a broader c...
Autores principales: | Hanna, Glenn J., Ruiz, Emily S., LeBoeuf, Nicole R., Thakuria, Manisha, Schmults, Chrysalyne D., Decaprio, James A., Silk, Ann W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653959/ https://www.ncbi.nlm.nih.gov/pubmed/32868898 http://dx.doi.org/10.1038/s41416-020-01044-8 |
Ejemplares similares
-
Predictors of immunotherapy benefit in Merkel cell carcinoma
por: Kacew, Alec J., et al.
Publicado: (2020) -
Cutaneous squamous cell carcinoma staging may influence management in users: A survey study
por: Patel, Vishal A., et al.
Publicado: (2021) -
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
por: Hanna, Glenn J., et al.
Publicado: (2020) -
Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E- selectin expression in human squamous cell carcinomas
por: Gehad, Ahmed, et al.
Publicado: (2012) -
Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses
por: Dowlatshahi, Mitra, et al.
Publicado: (2013)